| Avastin (Bevacizumab) in the Treatment of Metastatic Colorectal Cancer in Normal Clinical Use in the UK Population (NCT02542436) | Hoffmann-La Roche | 2015-09-01 |
| A Phase Ib Study of Humanized Anti-VEGF Monoclonal Antibody (Sevacizumab) Injection Plus FOLFIRI in Chinese Patients With Metastatic Colorectal Cancer (NCT02453464) | Jiangsu Simcere Pharmaceutical Co., Ltd. | 2015-08-01 |
| Safety, Tolerability and Pharmacokinetics of Oral Tablet of Irinotecan in Adult Patients With Solid Tumors (NCT03295084) | Dorte Nielsen | 2015-07-15 |
| Study of Trastuzumab-emtansine in Patients With HER2-positive Metastatic Colorectal Cancer Progressing After Trastuzumab and Lapatinib. (NCT03418558) | Fondazione del Piemonte per l'Oncologia | 2015-07-08 |
| Visualization of Anti-angiogenic Effects With Perfusion Computed Tomography (CTP) (NCT02511756) | Patrick Veit-Haibach | 2015-07-01 |
| Trial of Antigen Pulsed Dendritic Cells (APDC) in Metastatic Colorectal Cancer (NCT02503150) | Second Military Medical University | 2015-07-01 |
| Improving Informed Consent for Palliative Chemotherapy (NCT02282722) | Dana-Farber Cancer Institute | 2015-06-10 |
| Panitumumab-based Maintenance in Patients With RAS Wild-type, Metastatic Colorectal Cancer (Valentino) (NCT02476045) | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 2015-06-01 |
| Bevacizumab + Triplet Treatment for Untreated With Chemotherapy Metastatic Colorectal Cancer (NCT02497157) | Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan | 2015-05-21 |
| Assess the Efficacy of Pembrolizumab Plus Radiotherapy or Ablation in Metastatic Colorectal Cancer Patients (NCT02437071) | Memorial Sloan Kettering Cancer Center | 2015-04-01 |
| Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus Cetuximab (NCT02934529) | Ludwig-Maximilians - University of Munich | 2015-03-01 |
| Intravenous Ferric Carboxymaltose vs. Oral Iron Substitution in Patients With Metastatic Colorectal Cancer (CRC) and Iron Deficiency Anemia: a Randomized Multicenter Treatment Optimization Study. (NCT02469480) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2015-03-01 |
| Regorafenib in Metastatic Colorectal Cancer (NCT02466009) | University of Rochester | 2015-03-01 |
| PERMAD: Personalized Marker-driven Early Switch to Aflibercept in Patients With Metastatic Colorectal Cancer (NCT02331927) | University of Ulm | 2015-03-01 |
| Folfoxiri Plus Bev Followed by Reintroduction of Folfoxiri Plus Bev at Progression Versus Folfox Plus Bev Followed by Folfiri Plus Bev in mCRC (NCT02339116) | Gruppo Oncologico del Nord-Ovest | 2015-02-26 |
| Pretargeted Radioimmunotherapy in Metastatic Colorectal Cancer (NCT02300922) | Nantes University Hospital | 2015-01-27 |
| Prospective Translational Study Investigating Molecular Predictors of Resistance and Response to Regorafenib Monotherapy (NCT03010722) | Royal Marsden NHS Foundation Trust | 2015-01-01 |
| FOLFOXIRI With or Without Bevacizumab as First-line Treatment for Unresectable Liver-only Metastatic Colorectal Cancer Patients With RAS Mutation-type (NCT02350530) | Sun Yat-sen University | 2015-01-01 |
| A Phase 2 Study of Pembrolizumab (MK-3475) in Combination With Azacitidine in Subjects With Chemo-refractory Metastatic Colorectal Cancer (NCT02260440) | Anuradha Krishnamurthy | 2015-01-01 |
| Clinical Evaluation of PET-CT for Staging of Colorectal Lung Metastases (NCT02942901) | Lung Clinic Heckeshorn | 2015-01-01 |
| Safety, Tolerability and Pharmacokinetics of Recombinant Anti-epidermal Growth Factor Receptor(EGFR) Monoclonal Antibody in Patients With Metastatic Colorectal Cancer (NCT02211443) | Sinocelltech Ltd. | 2015-01-01 |
| Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutations (NCT02278133) | Array BioPharma | 2014-12-01 |
| Study of Anlotinib in Patients With Metastatic Colorectal Cancer（mCRC）(ALTER0703) (NCT02332499) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2014-12-01 |
| Prospective Observational Study of 1st and 2nd Line Vectibix® Use in RAS-wt mCRC Pts to Evaluate Pattern of Use and ORR (NCT02322736) | Amgen | 2014-11-21 |
| Safety and Effectiveness Study of Chemotherapy and Ziv-aflibercept to Treat Metastatic Colorectal Cancer (NCT01889680) | NSABP Foundation Inc | 2014-11-01 |
| Study Evaluating the Influence of LV5FU2 Bevacizumab Plus Anakinra Association on Metastatic Colorectal Cancer (NCT02090101) | Centre Georges Francois Leclerc | 2014-10-10 |
| Cetuximab Rechallenge in Irinotecan-pretreated mCRC, KRAS, NRAS and BRAF Wild-type Treated in 1st Line With Anti-EGFR Therapy (CRICKET). (NCT02296203) | Gruppo Oncologico del Nord-Ovest | 2014-10-01 |
| Evaluation of MGN1703 Maintenance Treatment in Patients With mCRC With Tumor Reduction During Induction Treatment (NCT02077868) | Mologen AG | 2014-09-01 |
| Chemotherapy-related Toxicity, Nutritional Status and Quality of Life (NCT02848807) | University Clinical Centre, Gdansk | 2014-09-01 |
| Study to Compare CAPTEM vs FOLFIRI as Second Line Treatment in Advanced, Colorectal Cancer Patients (NCT02414009) | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 2014-09-01 |
| Escalated Dose of Irinotecan in mCRC (NCT02256800) | Jaw-Yuan Wang, MD, PhD | 2014-08-13 |
| Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy (NCT02205398) | Novartis Pharmaceuticals | 2014-07-28 |
| TS-1 in Combination With Calcium Folinate in Patients With Heavily Pre-treated mCRC (NCT03517618) | TTY Biopharm | 2014-07-05 |
| Aflibercept and Chemotherapy as First Line Treatment for Metastatic Colorectal Cancer Assessable With DCE-US (PULSAR). (NCT02173990) | Centre Oscar Lambret | 2014-07-01 |
| Trial of FOLF(HA)Iri With Cetuximab in mCRC (NCT02216487) | Western General Hospital, Australia | 2014-06-01 |
| Clinical Trial of Combination Chemotherapy With Aflibercept in Patients With Advanced Colorectal Cancer (NCT02129257) | Hellenic Cooperative Oncology Group | 2014-05-26 |
| Ocular Blood Flow in Colorectal Cancer Patients (NCT02423785) | Medical University of Vienna | 2014-05-01 |
| Phase I/II Trial of Antagonism of HER in GI Cancer (NCT01862003) | University College, London | 2014-05-01 |
| SGI-110 in Combination With an Allogeneic Colon Cancer Cell Vaccine (GVAX) and Cyclophosphamide (CY) in Metastatic Colorectal Cancer (mCRC) (NCT01966289) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2014-04-14 |
| FOLFOXIRI Compared to FOLFOX in First Line Treatment of Metastatic Colorectal Cancer (NCT02128425) | Sun Yat-sen University | 2014-04-01 |
| Maintenance Therapy With 5-FU/FA Plus Panitumumab vs. 5-FU/FA Alone After Prior Induction and Re-induction After Progress for 1st-line Treatment of Metastatic Colorectal Cancer (NCT01991873) | AIO-Studien-gGmbH | 2014-04-01 |
| Image Guided Treatment Optimization With Cetuximab for Patients With Metastatic Colorectal Cancer (NCT02117466) | Amsterdam UMC, location VUmc | 2014-04-01 |
| Sym004 vs Standard of Care in Subjects With Metastatic Colorectal Cancer (NCT02083653) | Symphogen A/S | 2014-03-06 |
| A Phase II Study of Ziv-aflibercept in Combination With Capecitabine/Oxaliplatin (XELOX) Chemotherapy in the Front-Line Treatment of Patients With Metastatic Colorectal Cancer (NCT02079220) | James J Lee | 2014-03-01 |
| A Study of Systemic Chemotherapy With/Without HAI in Patients With Initially Unresectable Colorectal Liver Metastasis (NCT02102789) | Yuhong Li | 2014-03-01 |
| FOLFOXIRI With or Without Cetuximab as First-line Treatment of Patients With Non-resectable Liver - Only Metastatic Colorectal Cancer (NCT02063529) | Sun Yat-sen University | 2014-02-01 |
| Regorafenib in Metastatic Colorectal Cancer : a Cohort Study in the Real-life Setting (NCT02310477) | Centre Oscar Lambret | 2014-02-01 |
| Recombinant Anti-tumor and Anti-virus Protein for Injection Plus Xeloda in Treatment of Metastatic Colorectal Cancer (NCT02068131) | The Affiliated Hospital of the Chinese Academy of Military Medical Sciences | 2014-02-01 |
| Retrospective Evaluation of 5-FU Exposure Optimization in CRC Patients (NCT02055560) | Saladax Biomedical, Inc. | 2014-01-01 |
| Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Treatment Combining Cetuximab With FOLFOX or FOLFIRI in RAS and B-RAF WT Tumors (NCT01858662) | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | 2014-01-01 |
| Treatment After Irinotecan-based Frontline Therapy: Maintenance With Erbitux (in Patients wtRAS mCRC) (NCT02404935) | UNICANCER | 2013-11-22 |
| Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors (NCT01927341) | Pfizer | 2013-11-19 |
| A Study Of PF-05212384 Plus Irinotecan Vs Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal Cancer (NCT01925274) | Pfizer | 2013-11-15 |
| Identification of Predictive Biomarker of Regorafenib in Refractory Colorectal Cancer (NCT01996969) | Seoul National University Hospital | 2013-10-01 |
| A Phase II Study of IMMU 130 in Patients With Metastatic Colorectal Cancer (NCT01915472) | Gilead Sciences | 2013-09-01 |
| Study to Determine the Efficacy of Regorafenib in Metastatic Colorectal Cancer Patients and to Discover Biomarkers (NCT01949194) | Gerald Batist | 2013-09-01 |
| Safety Study of Bevacizumab Plus Chemotherapy To Treat Metastatic Colorectal Cancer (NCT01912443) | Sun Yat-sen University | 2013-08-01 |
| Second-line FOLFOX With or Without Regorafenib in mCRC Patients Failed to First-line Irinotecan Plus Fluoropyrimidines (NCT01786538) | Asan Medical Center | 2013-06-01 |
| Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Bevacizumab With FOLFOX or FOLFIRI. (NCT01858649) | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | 2013-05-01 |
| Study of Microcirculatory Effects of Bevacizumab in Patients Treated for Metastatic Colon Cancer or Glioblastoma (NCT01810744) | Centre Georges Francois Leclerc | 2013-05-01 |
| Cohort Study to Assess Impact of Chemotherapy Plus Bevacizumab on Health Related Quality of Life in First Line Metastatic Colorectal Cancer (NCT02842294) | Centre Hospitalier Universitaire de Besancon | 2013-05-01 |
| Cetuximab Rechallenge Study (NCT01832467) | Chinese University of Hong Kong | 2013-04-24 |
| Study of Lurbinectedin (PM01183) in Combination With Capecitabine in Patients With Metastatic Breast Cancer (MBC), Pancreatic Cancer (PC) or Metastatic Colorectal Cancer (CRC). (NCT02210364) | PharmaMar | 2013-04-01 |
| A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer (NCT01767857) | Janssen Research & Development, LLC | 2013-03-31 |
| Study for Validation of Immunological Biomarkers in Patients With Metastatic Colorectal Cancer (NCT02817178) | Centre Hospitalier Universitaire de Besancon | 2013-03-01 |
| Study of Labetuzumab Govitecan in Participants With Metastatic Colorectal Cancer (NCT01605318) | Gilead Sciences | 2013-02-12 |
| Vemurafenib and Panitumumab Combination Therapy in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer (NCT01791309) | Memorial Sloan Kettering Cancer Center | 2013-01-01 |
| Endostar Combined With mFOLFOX6 for First-line Treatment of Metastatic Colorectal Cancer (NCT01832948) | Zhejiang Cancer Hospital | 2013-01-01 |
| Biomarker Directed Treatment in Metastatic Colorectal Cancer (NCT01703390) | Arbeitsgemeinschaft medikamentoese Tumortherapie | 2012-12-04 |
| Adjuvant Aflibercept for Metastatic Colorectal Cancer (NCT01669720) | Brown University | 2012-12-01 |
| A Phase 2 Study of Panitumumab in Patients With Cetuximab-refractory Metastatic Colorectal Cancer (NCT01801904) | National Cancer Institute, Naples | 2012-12-01 |
| Hepatic Arterial Infusion With FOLFOX Alone or in Combination With IV Chemotherapy in Colon Cancer With Liver Metastasis (NCT02345746) | Western Regional Medical Center | 2012-12-01 |
| Metastatic Colorectal Cancer Database (NCT04031625) | Centre Georges Francois Leclerc | 2012-11-26 |
| Cetuximab for Elderly Patients With mCRC (NCT01718808) | Swiss Cancer Institute | 2012-11-01 |
| Metformin and 5-fluorouracil for Refractory Colorectal Cancer. (NCT01941953) | Instituto do Cancer do Estado de São Paulo | 2012-11-01 |
| PROSPECT-C: A Study of Biomarkers of Response or Resistance to Anti-EGFR Therapies in Metastatic Colorectal Cancer (NCT02994888) | Royal Marsden NHS Foundation Trust | 2012-11-01 |
| Evaluation of Hypertension as a Predictor of Efficacy Bevacizumab in Metastatic Breast Cancer and Colorectal Cancer (NCT01733628) | Spanish Breast Cancer Research Group | 2012-10-23 |
| Dual Targeting of EGFR With Cetuximab and Afatinib to Treat Refractory wtKRAS Metastatic Colorectal Cancer (NCT01919879) | UNICANCER | 2012-10-01 |
| "Cancersensor" Chemotherapy (NCT01693861) | Institut National de la Santé Et de la Recherche Médicale, France | 2012-10-01 |
| Phase I / II Study of Enadenotucirev by Sub-acute Fractionated IV Dosing in Cancer Patients (NCT02028442) | Akamis Bio | 2012-09-20 |
| Medical Records Review to Describe the Patterns of KRAS Testing and Vectibix Use in Europe (NCT01791361) | Amgen | 2012-09-19 |
| P13Kinase Inhibitor BKM120 in Combination With Panitumumab in Metastatic/Advanced RAS-Wild Type Colorectal Cancer. (NCT01591421) | Canadian Cancer Trials Group | 2012-09-06 |
| "Cancersensor" Metastasis Resection (NCT01693848) | Institut National de la Santé Et de la Recherche Médicale, France | 2012-09-01 |
| Biweekly Versus Triweekly Raltitrexed With Oxaliplatin (With or Without Bevacizumab) in First-line Metastatic Colorectal Cancer (NCT02821559) | Centre Hospitalier Universitaire de Besancon | 2012-08-09 |
| "Cancersensor": Circadian Rhythms (NCT01693835) | Institut National de la Santé Et de la Recherche Médicale, France | 2012-08-01 |
| Phase I/II Study of Capecitabine Plus Aflibercept to Treat Metastatic Colorectal Cancer (NCT01661972) | John Strickler, M.D. | 2012-08-01 |
| Evaluation of Trastuzumab in Combination With Lapatinib or Pertuzumab in Combination With Trastuzumab-Emtansine to Treat Patients With HER2-positive Metastatic Colorectal Cancer (NCT03225937) | Fondazione del Piemonte per l'Oncologia | 2012-08-01 |
| Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors (NCT01576666) | Novartis Pharmaceuticals | 2012-07-01 |
| Study to Evaluate the Efficacy and Safety of FOLFIRI-AD in Patients With Metastatic Colorectal Cancer UGT1A Genotype 1 (NCT01639326) | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | 2012-07-01 |
| An Observational Study of Bevacizumab in Chinese Patients With Metastatic Colorectal Cancer (NCT01860144) | Peking University | 2012-06-01 |
| A Study of IMM-101 in Combination With Radiation Induced Tumour Necrosis in Colorectal Cancer (NCT01539824) | Immodulon Therapeutics Ltd | 2012-05-30 |
| BKM120 + mFOLFOX6 in Advanced Solid Tumors With Expansion Cohort Pancreatic Cancer (NCT01571024) | UNC Lineberger Comprehensive Cancer Center | 2012-05-01 |
| Nordic 8 - A Phase II Trial (NCT01867697) | Per Pfeiffer | 2012-05-01 |
| Study of TLBZT Based Herbal Therapy Plus Chemotherapy for Metastatic Colorectal Cancer (NCT01975454) | Shanghai University of Traditional Chinese Medicine | 2012-04-01 |
| Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO) (NCT01507545) | Morphotek | 2012-03-27 |
| Individual Dosage Selection of Irinotecan (CPT-11) Based on UGT1A1 Genotype in Metastatic Colorectal Cancer Patients (NCT01523431) | The Affiliated Hospital of the Chinese Academy of Military Medical Sciences | 2012-03-08 |
| European Physician Survey of EGFR Inhibitor Prescribing Patterns (NCT01652833) | Amgen | 2012-03-01 |
| Circulating Regulatory Lymphocytes and Outcome of Metastatic Colorectal Cancer Patients (NCT01533740) | University of Rome Tor Vergata | 2012-03-01 |
| A Population-based Prospective Study of Metastatic Colorectal Cancer (CRC) Patients in Finland (NCT01531621) | Pia Osterlund | 2012-02-01 |
| Pharmacokinetics and Metabolic Activation of Capecitabine (NCT01579357) | Arbeitsgemeinschaft medikamentoese Tumortherapie | 2012-02-01 |